文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

阿奇霉素联合季节性疟疾化学预防对疟疾、急性呼吸道、胃肠道和皮肤感染的保护持续时间

The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali.
PubMed 文献 · Clin Infect Dis · 2021-01-01

结果显示阿奇霉素对疟疾、胃肠炎和肺炎的额外保护仅限于给药后前2周,对伴皮肤症状的非疟疾发热保护持续至28天,对住院和死亡无保护证据。

要点

  • 阿奇霉素对疟疾保护仅限给药后2周内,保护效24.2%。
  • 胃肠炎和肺炎保护也仅限前2周,分别降低29.9%和34.3%。
  • 伴皮肤症状的非疟疾发热保护持续至28天,保护效46.3%。

核心结论

  • 阿奇霉素群体给药的保护作用广泛但短暂,需考虑不同病因发病和死亡高峰不同步来优化给药时机。

主要发现

  • 与SMC加安慰剂相比,SMC加阿奇霉素对住院和死亡无保护证据。
  • 对疟疾的额外保护仅限于给药后前2周,保护效24.2%(95%CI:17.8%-30.1%)。
  • 胃肠炎和肺炎在给药后前2周分别降低29.9%(95%CI:21.7%-37.3%)和34.3%(95%CI:14.9%-49.3%)。
  • 对伴皮肤症状的非疟疾发热保护持续至28天,保护效46.3%(95%CI:35.1%-55.6%)。

临床怎么用

  • 阿奇霉素群体给药若用于促进儿童生存,需针对不同病因发病高峰安排给药时机以最大化效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mass drug administration (MDA) with azithromycin (AZ) is being considered as a strategy to promote child survival in sub-Saharan Africa, but the mechanism by which AZ reduces mortality is unclear. To better understand the nature and extent of protection provided by AZ, we explored the profile of protection by time since administration, using data from a household-randomized, placebo-controlled trial in Burkina Faso and Mali. METHODS: Between 2014 and 2016, 30 977 children aged 3-59 months received seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine and either AZ or placebo monthly, on 4 occasions each year. Poisson regression with gamma-distributed random effects, accounting for the household randomization and within-individual clustering of illness episodes, was used to compare incidence of prespecified outcomes between SMC+AZ versus SMC+placebo groups in fixed time strata post-treatment. The likelihood ratio test was used to assess evidence for a time-treatment group interaction. RESULTS: Relative to SMC+placebo, there was no evidence of protection from SMC+AZ against hospital admissions and deaths. Additional protection from SMC+AZ against malaria was confined to the first 2 weeks post-administration (protective efficacy (PE): 24.2% [95% CI: 17.8%, 30.1%]). Gastroenteritis and pneumonia were reduced by 29.9% [21.7; 37.3%], and 34.3% [14.9; 49.3%], respectively, in the first 2 weeks postadministration. Protection against nonmalaria fevers with a skin condition persisted up to 28 days: PE: 46.3% [35.1; 55.6%]. CONCLUSIONS: The benefits of AZ-MDA are broad-ranging but short-lived. To maximize impact, timing of AZ-MDA must address the challenge of targeting asynchronous morbidity and mortality peaks from different causes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Phiri MD, Cairns M, Zongo I, et al. The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali. Clin Infect Dis. 2021. PMID: 33417683. doi:10.1093/cid/ciaa1905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。